Molecular Docking and Toxicity Test of Apigenin Derivative Compounds as an Anti-Aging Agent

Esti Mumpuni* and Esti Mulatsari
Faculty of Pharmacy, University of Pancasila, South of Jakarta, 12640, INDONESIA

Article history: Received in revised form 26-03-2018 Accepted 20-04-2018 Available online June 20, 2018

Cite this article as: Mumpuni E and Mulatsari E. Molecular Docking and Toxicity Test of Apigenin Derivative Compounds as an Anti-Aging Agent. J Applied Chem. Sci. 2018, 5(1):409-413, DOI: https://dx.doi.org/10.22341/jacs.on.00501p409

p-ISSN: 2089-6328, e-ISSN: 2580-1953 © 2018 JACSONline GP. All right served

ABSTRACT

The intrinsic factors that caused aging are enzymes such as hyaluronidase and elastase by oxidative stress mechanism. Antioxidants are the bioactive compounds which are highly important to fight against oxidative stress that can cause aging. Modified compounds of apigenin have reported can act as an antioxidant. The aim of this study was to determine candidate of apigenin derivative compounds that were potential to inhibit hyaluronidase and elastase enzyme by using molecular docking method with human target protein with pdb.id : 2JIE and 5JMY. Molecular docking was done using windows operating system with several softwares, i.e: PLANTS, YASARA and MarVinSketch. Visualization of bonding modes between the ligand and amino acid residues was done with PyMol. Of the 50 apigenin derivative compounds tested, obtained 9 compounds with lower docking scores than apigenin in inhibiting hyaluronidase and 5 compounds in inhibiting elastase enzyme. 3’6-diamineapigenin had the lowest docking score (-62.39) in inhibiting hyaluronidase enzyme (2JIE) and 3’amineapigenin had the lowest docking score (-91.31) in inhibiting elastase enzyme (5JMY). The binding interactions of the actively docked conformations of the ligand and the target protein have been identified and showed the most amino acid residues that c

Keywords: apigenin, antioxidant, anti-aging, molecular docking

* Corresponding author: esti_mumpuni@yahoo.com / Tel: (021) 7864727-28

1. Introduction

Aging is a process of gradual disappearance of the network's ability to repair or replace itself and maintain its structure, as well as its normal function. Skin can experience aging, one of which is marked by the emergence of wrinkles (wrinkle). It does not occur solely because of the increasing age of the skin itself, but can also occur due to external factors. Aging can also be caused by various factors, i.e factors that come from within the body itself (intrinsic factor) or factors that come from outside body (extrinsic factor). The intrinsic factors include the activity of certain enzymes. Increased activity of certain enzymes involved in the aging process of the skin includes elastase, hyaluronidase, and collagenase (Thring et al., 2009).

Elastase is a proteolytic enzyme involved in the degradation of the extracellular matrix (ECM) that includes elastin. Elastin provides much of the elastic recoil properties of skin, arteries, lungs, and ligaments. Loss of elastin is a major part of what causes visible signs of aging (wrinkles, sagging) in the skin (Thring et al., 2009).

Hyaluronic acid or hyaluronan is one of the important components of the tissue matrix substance and has a role in the development, growth, and repair of damaged tissue (Pogrel et al., 1996). Meanwhile, elastin plays a role in the maintenance of skin elasticity, but elastase can degrade it (Thring et al., 2009). Degradation of the Extracellular Matrix (ECM) has been directly linked to skin aging and is correlated with an increase in activity of certain enzymes involved in skin aging (Longo et al., 2003; Makrantonaki et al., 2010). Inhibition of these enzymes is crucial in anti-aging prevention (Ndlovu et al., 2013).

Fig. 1. Based structure of apigenin

Apigenin is the main organic compound of flavonoids contained in celery belonging to the flavon group (Fig.1). The compound that has three aromatic rings with the -OH- grouped branches. Apigenin can be synthesized and developed into a potent antioxidant compound (Seyoum et al., 2006; Ray, 2012). Several studies related to the development of apigenin structure have been done to...
increase the ability of antioxidant activity (Perwira et al., 2015; Mumpuni et al., 2017). Mumpuni et al. (2017) has modified the structure of the apigenin and predicted its ability as antioxidant using the QSAR method (Semiempirical Austin Model 1). Of the 90 modified compounds of apigenin, obtained 50 compounds that have better activity as antioxidant than apigenin.

Antioxidants are the bioactive compounds which are highly important to fight oxidative stress that can produce free radicals which are affected for various diseases such as heart attack, cancer, cataract, atherosclerosis, neurodegenerative disease, decreased kidney function, diabetes, and premature aging (Uttara et al., 2009).

In this study carried out analysis of apigenin derivative compounds that have been reported by Mumpuni et al. (2017) as an antioxidant that plays a role in inhibition of hyaluronidase and elastase enzyme using molecular docking method with enzyme of hyaluronidase and elastase that present in protein data bank (PDB) data base with id 2JIE and 5JMY (Fig. 2). Visualization and elucidation of the bonding mode between a ligand and target protein to determine amino acids residues that play a role in ligand-protein affinity in the inhibition process. In this study will also be screened about the toxicity of apigenin derivative compounds using a protox webserver.

2. Materials and Methods

2.1. Tools

The hardware used in this research is a laptop with AMD A6 processor, 4 GB RAM, Windows 10, 64-bit operating system. Software used includes: PLANTS, Marvin Skech, PyMol, and YASARA.

2.2. Materials

Fifteen (50) 2D structures of apigenin derivative compounds of research results by Mumpuni et al. (2017), crystalline form of protein with PDB ID : 5JMY and 2JIE.

2.3. Research Procedure

2.3.1. Preparation of Proteins and Ligands

Preparation of proteins and ligands was done using YASARA software. Proteins with 5JMY.pdb.id and 2JIE.pdb.id that have been downloaded from database of Protein Data Bank loaded on YASARA worksheets, proteins, and native ligands are separated and saved with file names protein.mol2 and ref_ligand.mol2. Native ligands and new ligands (apigenin derivative compounds) are continuously prepared to form conformations using Marvin Skech and saved with file name ligand.mol2.

2.3.2. Docking protocol validation

The docking protocol validation is performed by calculating the Root Mean Square Deviation (RMSD) values between the native ligand of pdb.id with the conformation of the docked ligand. Docking protocol is considered good and can be used for the further docking process if it has a value of 2 - 2.5 Å, closer to 0 considered the alignment is better. This validation result used to configure the plantsconfig.file.

2.3.2. Molecular docking

The docking process has done with standard procedure of molecular docking using PLANTS (Korb et al., 2009; Purnomo, 2010). Validated protocol (plantsconfig.file), ref_ligand.mol2, protein.mol2, and ligand.mol2 prepared as input data. Docking process has done by typing commands on cmd. The PLANTS application will read the validated protocol and start the docking process. Docking process obtained docking scores as output data that showed the energy of the ligand in binding to the target protein. The more negative of docking scores the affinity of the ligand binding to the protein is stronger.

2.3.2. Toxicity Screening

Toxicity screening has done using ProTox webserver, test compounds were prepared with SMILES file type. Then input on ProTox webserver then run the calculating program of toxicity. The toxicity level performed in LD50, mg/kg unit.

3. Results and Discussion

The RMSD value obtained from the docking protocol validation process was 1.1 Å for 5JMY enzyme and 1.69 Å for the 2JIE enzyme, this value is eligible for the protocol to be used for further docking process. The alignment between the reference ligand and the conformation of the docked ligand is very good (Fig. 3). The docking process of apigenin derivative compounds was performed on 50 apigenin derivative compounds that were tested in silico by QSAR method that having better antioxidant activity than apigenin by Mumpuni et al. (2017) (Table 1). Of the 50 compounds tested, obtained 9 compounds having a lower docking score than apigenin in inhibiting hyaluronidase enzyme i.e 3,6-diethoxy apigenin, 3'-amine apigenin, 3,6-dimethoxy apigenin, 3,6-dipropoxy apigenin, 3'-ethoxy apigenin, 3'-fluoro apigenin, 3'6 diamine apigenin, 6-amine apigenin,
Table 1. Docking score of apigenin derivative compounds

| No | Apigenin derivative compounds (test ligand) | Hyaluronidase (2JIE) | Elastase (5JMY) | LD<sub>50</sub> (mg/Kg) |
|----|---------------------------------------------|----------------------|-----------------|----------------------|
| 1. | 3'3'6 trimethoxy apigenin                    | -49.64               | -57.80          | 5000                 |
| 2. | 3'6 diethoxy apigenin                       | -57.40               | -76.31          | 5000                 |
| 3. | 3' amine apigenin                           | -57.58               | -91.31          | 3919                 |
| 4. | 3 amine apigenin                            | -49.21               | -72.05          | 3919                 |
| 5. | 3 ethoxy apigenin                           | -48.08               | -77.21          | 5000                 |
| 6. | 3 ethyl apigenin                            | -51.23               | -77.71          | 3919                 |
| 7. | 3' isopropyl apigenin                       | -51.15               | -72.96          | 3919                 |
| 8. | 3 isopropoxy apigenin                       | -49.08               | -73.14          | 3919                 |
| 9. | 3' methyl apigenin                          | -52.48               | -73.7           | 3919                 |
| 10. | 3' methoxy apigenin                         | -52.47               | -79.98          | 3919                 |
| 11. | 3' propyl apigenin                          | -51.27               | -82.29          | 3919                 |
| 12. | 3 propoxy apigenin                          | -46.30               | -75.31          | 5000                 |
| 13. | 3,3',6-triethyl apigenin                    | -47.74               | -75.51          | 159                  |
| 14. | 3,3',6-triethoxy apigenin                   | -44.73               | -59.77          | 5000                 |
| 15. | 3,3',6-trisopropyl apigenin                 | -51.25               | -73.18          | 159                  |
| 16. | 3',3',6-trisopropoxy apigenin               | -42.65               | -72.59          | 5000                 |
| 17. | 3',3',6-trimethyl apigenin                  | -50.66               | -75.81          | 159                  |
| 18. | 3',3',6-tripropyl apigenin                  | -48.08               | -70.90          | 159                  |
| 19. | 3',3',6-tripropoxy apigenin                 | -47.95               | -62.57          | 5000                 |
| 20. | 3',3'-diethyl apigenin                      | -48.85               | -80.59          | 159                  |
| 21. | 3',3'-diisopropyl apigenin                  | -51.15               | -73.94          | 159                  |
| 22. | 3',3'-dimethyl apigenin                     | -50.79               | -86.94          | 3919                 |
| 23. | 3',3'-dipropyl apigenin                     | -52.78               | -87.74          | 159                  |
| 24. | 3',3'-dipropoxy apigenin                    | -50.38               | -71.62          | 5000                 |
| 25. | 3',3'-dibromopropyl apigenin                | -50.37               | -69.35          | 159                  |
| 26. | 3',3'-dimethyl apigenin                     | -50.02               | -72.24          | 159                  |
| 27. | 3',3'-dimethoxy apigenin                    | -58.83               | -82.98          | 5000                 |
| 28. | 3',3'-dipropyl apigenin                     | -49.60               | -75.58          | 159                  |
| 29. | 3',3'-dipropoxy apigenin                    | -58.83               | -82.97          | 5000                 |
| 30. | 3' ethoxy apigenin                          | -58.85               | -82.97          | 4000                 |
| 31. | 3' fluoro apigenin                          | -57.44               | -86.97          | 3919                 |
| 32. | 3' chloro apigenin                          | -55.88               | -81.80          | 1070                 |
| 33. | 3',3'-diethoxy apigenin                     | -53.82               | -83.14          | 3919                 |
| 34. | 3',3'-dimethoxy apigenin                    | -48.85               | -83.29          | 3919                 |
| 35. | 3',3'-dipropoxy apigenin                    | -53.83               | -83.28          | 5000                 |
| 36. | 3'6 diamine apigenin                        | -62.39               | -85.21          | 1070                 |
| 37. | 6-amineapigenin                             | -57.14               | -83.65          | 1070                 |
| 38. | 6-ethyl-apigenin                            | -55.81               | -80.17          | 3919                 |
| 39. | 6-ethoxy apigenin                           | -53.88               | -80.73          | 4000                 |
| 40. | 6-propoxy-apigenin                          | -49.39               | -75.75          | 4000                 |
| 41. | 6-methyl-apigenin                           | -56.71               | -78.86          | 3919                 |
| 42. | 6-methoxy apigenin                          | -50.83               | -75.72          | 4000                 |
| 43. | 33' diame apigenin                          | -50.76               | -76.02          | 3919                 |
| 44. | 33' diethoxy apigenin                       | -51.53               | -74.58          | 5000                 |
| 45. | 33' disopropoxy apigenin                    | -51.05               | -74.49          | 159                  |
| 46. | 33' dimethoxy apigenin                      | -51.19               | -74.49          | 5000                 |
| 47. | 33'6 triamine apigenin                      | -53.63               | -74.39          | 3919                 |
| 48. | 36 diamine apigenin                         | -48.16               | -67.84          | 3919                 |
| 49. | 36 diethyl apigenin                         | -51.56               | -72.07          | 159                  |
| 50. | 36 disopropoxy apigenin                     | -50.34               | -68.79          | 159                  |
| 51. | Apigenin                                    | -56.15               | -84.80          | 2500                 |

6-methyl-apigenin and 5 compounds that having a lower docking score than apigenin in inhibiting elastase enzyme i.e 3'-amine apigenin, 3,3'-dimethyl apigenin, 3,3'-dipropyl apigenin, 3'-fluoro apigenin, 3,6-diamine apigenin. The 3',6-diamine apigenin had the lowest docking score in inhibiting hyaluronidase enzyme (2JIE) and the 3’-amineapigenin had the lowest docking score in inhibiting elastase enzyme (5JMY). The chemical structures of these compounds are shown in Fig. 4. Through molecular docking can be known the potential of compounds to be a drug candidates based on the affinity of binding to target proteins (Kastritis et al., 2012). Binding affinity is an important
Fig. 4. Structure of (A) 3'6-diamine apigenin (B) 3'amine apigenin aspect to be considered in molecular and macro molecular interactions (Seo et al., 2014). This binding affinity was illustrated by the value of the docking score. Lower binding affinities indicate that a compound requires less energy to engage in binding or interaction. In other words, the lower affinity value of binding increases the potential for binding to the target protein (Baker et al., 2007; Tassa et al., 2010). Score docking of 3'6 diamine apigenin and 3'amine apigenin were -62.39 and -91.31 (Table 1). These were the lowest score than the others derived compounds of apigenin. Its considered that 3'6 diamine apigenin and 3'amine apigenin have the best affinity in the binding site of anti-aging receptor 2JIE and 5JMY respectively. The negative value of binding energy change (ΔG) reveals that the binding process is spontaneous, it can fit well in the binding pocket receptor forming most stable drug receptor energetically (Kumar et al., 2014). Larger the negative value of binding energy, greater the chemical be accepted as a drug (Balavignesh et al., 2013).

Fig. 5. Hydrophobic areas (green) and hydrogen bond mapping (purple) in binding pocket of ligand-receptor (A) apigenin – 2JIE (B) apigenin – 5JMY (C) 3'6-diamine apigenin – 2JIE (D) 3'amine apigenin – 5JMY

The better affinity was due to the replacement of substituent affecting the properties of the ligand, based on the receptor properties mapping showed in Fig. 5. It was seen that the binding pocket of the 5JMY receptor was more hydrophobic than the binding pocket of the 2JIE receptor (green). The substitution of hydrogen had an effect on the lipophilicity of ligand, replacing H atom with an amine group at position 3' have made the log P value of 3'amine apigenin (2.002) not much different from apigenin (2.1). A large log P value makes 3'amine apigenin had a good interaction in binding pocket of the 5JMY receptor. Whereas replacement of hydrogen with amine groups at positions 3' and 6 on apigenin actually decreases the log P value of 3'6-diamine apigenin (1.5). It makes the hydrophobicity of 3'6-diamine apigenin was lower than apigenin. 3'6-diamine apigenin had a better affinity in the binding pocket of the 2JIE receptor. The log P value could be used to show the ability of a molecule to penetrate a biological membrane that was like a fat layer (Hansch et al., 1972).

Fig. 6. Hydrogen bond (red) and Van Der Walls interaction (blue) of ligand and active amino acid residues of the receptor (A) apigenin – 2JIE (B) apigenin – 5JMY (C) 3'6-diamine apigenin – 2JIE (D) 3'amine apigenin – 5JMY

The binding interactions of the most active docked conformation of the ligands of apigenin derivative compound and the target proteins have been identified using PyMol. Checked one by one all amino acids within 4 Å of the active site of the target protein, the important binding interactions were identified. The interaction of ligands with the binding pocket receptor is shown in Fig. 5. Apigenin and 3' amine apigenin occupied the same binding pocket of the 5JMY receptor with some active amino acid residues i.e THR_708, ASP_709, HIS_711, ARG_222, VAL_710, ARG_102, ARG_110, ASN_542, PHE_544. Hydrogen bonds formed between apigenin and active amino acid residue ASP_709 and VAL_710 with distances 1.89 and 2.1 Å respectively, whereas in 3'amine apigenin formed a hydrogen bond with active amino acid residue VAL_710 with distance 3.23 Å (Fig. 6). Apigenin and 3'6-diamine a pigenin occupied the same binding pocket of 2JIE receptor with some active amino acid residues i.e LUE_672, THR_673, HIS_671, SER_634, ALA_633, THR_632, ILE_631, ALA_645, TRP_657, ALA_648, ALA_760, GLU_762, VAL_763, ALA_688, TYR_687, LYS_727, LEU_720, TYR_701, ILE_698, VAL_743, and LEU_741. Apigenin formed Van Der Walls interactions with active amino acid residue ASP_709 and VAL_710 with distances 1.89 and 2.1 Å respectively, whereas in 3'amine apigenin formed a hydrogen bond with active amino acid residue VAL_710 with distance 3.23 Å (Fig. 6). Apigenin and 3'6-diamine a pigenin occupied the same binding pocket of 2JIE receptor with some active amino acid residues i.e LUE_672, THR_673, HIS_671, SER_634, ALA_633, THR_632, ILE_631, ALA_645, TRP_657, ALA_648, ALA_760, GLU_762, VAL_763, ALA_688, TYR_687, LYS_727, LEU_720, TYR_701, ILE_698, VAL_743, and LEU_741. Apigenin formed Van Der Walls interactions with active amino acid residue HIS_671 and LEU_672 with distance 2.17 Å and 1.62 Å, whereas 3'6-diamine apigenin forming a hydrogen bond with active amino acid residue GLU_762 with distance 0.74 Å and formed a Van Der Walls interaction with active amino acid residue VAL_763 with
distance 1.97 Å. In addition to hydrogen bonding, the activity of ligand inhibiting on receptor was also influenced by electronic bonding, hydrophobic and van der walls interaction (Khalid et al., 2013).

Toxicity of compounds is very important on determining a candidate of a drug. So, in this research has done tested the toxicity of apigenin derivative compounds (Table 1). The most apigenin derivative compounds have very low toxicity, included the both of active compounds i.e 3’6-diamine apigenin and 3’amine apigenin.

4. Conclusion

The most active conformation of apigenin derivative compound as antioxidant acting as anti-aging agent is the 3’-diamine apigenin that active to inhibit hyaluronidase enzyme (2JIIE) and the 3’amine apigenin that active to inhibit elastase enzyme (5JM)

Acknowledgement

Authors would like to thanks to the Dean of Faculty of pharmacy. Pancasila University, on grant funds to complete this research and Dr. Hari Purnomo, Faculty of Pharmacy, Gadjah Mada University, for his guidance to complete this research.

References

Baker J, Woolfson D, Musckett F, Stoneman R, Urbaniak M, & Caddick S. 2007. Protein–Small Molecule Interactions in Neocarzinostatin, the Prototypical Endiine Chromoprotein Antibiotic. ChemBioChem, 8: 704-717. DOI: https://doi.org/10.1002/cbic.200600534

Balavignesh V, Srinivasan E, Ramesh Babu NG, and Saravanan N. 2013. Molecular docking study on NS5B polymerase of hepatitis c virus by a screening of volatile compounds from acacia concinna and ADMET prediction. Int J Pharm Life Sci, 4: 2548-2558.

Hänisch TW, Shahin IS, and Schawlow AL. 1972. Spectrum of H. Hydrogen. Balmer Spectrum. Nature 235, 63.

Khalid A, Kalsoom S, and Riaz, N. 2013. Design and Molecular Docking of Antioxidant Lead Compound and its Analogues Acting as Human Tyrosine Kinase Inhibitors. J Pharm. and Bio Sci, 5: 75-80. DOI: https://doi.org/10.9790/3008-00547580

Kastritis P, and Bonviv A. 2012. On the binding affinity of macro-molecular interactions: daring to ask why proteins interact. J Royal Society Interface, 10, 1-27. DOI: https://doi.org/10.1098/rsif.2012.0835

Korb O, Stutzle T, Exner TE. 2009. Empirical scoring functions for advanced-protein ligand docking with PLANTS. J Chem. Inf Model 49: 84-96. DOI: https://doi.org/10.1021/ci800298z

Kumar KM, Anitha P, Sivasakthi V, Bag S, Lavanya P, Anbarasu A. In silico study on penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens. 2014. Biotech, 4: 241-251. DOI: https://doi.org/10.1007/s13205-013-0147-z

Longo V, Finch C. Evolutionary medicine: From dwarf model systems to healthy centenarians?. 2003. Sci, 299: 1342–1346. DOI:10.1126/science.1077991. DOI: https://doi.org/10.1126/science.1077991

Makrantonaki E, Brink T, Zampeli V, Elewa R, Milo D, Bossini A. Identification of biomarkers of human skin ageing in both genders. Wnt signalling - a label of skin ageing?, 2010. PLoS ONE.; 7(11): e50393. DOI: https://doi.org/10.1371/journal.pone.0050393

Mumpuni E, Mulatsari E. 2017. QSAR Analysis on Apigenin Derivative Compounds as Antioxidant Using Semiempirical Austin Model 1. Asian J of Chem, 29: 1499 - 1505. DOI: https://doi.org/10.14233/ajchem.2017.20535

Ndlovu G, Fouche G, Tselanyane M, Cordvier W, Steenkamp V. 2013. In vitro determination of the anti-aging potential of four Southern African medicinal plants. BMC Complement Altern Med, 13: 1–7. DOI: https://doi.org/10.1186/1472-6882-13-304

Perwira G, Kasmud, Hadiprawiro S. 2015. Analisis Hubungan Kuantitatif Struktur dan Aktivitas Antioksidan Senyawa Turunan Apigenin. Indo. J. Chem. Sci, 4: 212 - 216

Pogrel M, Lowe M, Stern R. 1996. Hyaluronan (hyaluronic acid) in human saliva. Arch Oral Biol, 41: 667–671. DOI: https://doi.org/10.1016/S0003-9969(96)00050-7

Purnomo H. 2014. Desain Molekul Antibiotika. Pustaka Pelajar, Yogyakarta.

Ray S. 2012. A Theoretical Study Of 1,1-diphenyl-2-picrylhydrazyl (DPPH) Radical Scavenging Activities Of Flavonoids Using Electrophoretical State Atom (E-State) Parameters. Int J Pharm Bio Sci, 3: 543-550. India: Division of Pharmaceutical Chemistry, Dr. B C Roy College of Pharmacy & Allied Health Sciences.

Seo M H, Park J, Kim E, Hohng S, and Kim HS. 2014. Protein conformational dynamics dictate the binding affinity for a ligand. Nature Communications, 1-7. DOI: https://doi.org/10.1038/ncomms4724

Seyoum A, Asres K, and El-Fiky F.K. 2006. Structure-radical Scavenging Activity Relationships of Flavonoids. Phytochemistry, 67: 2058-2070. DOI: https://doi.org/10.1016/j.phytochem.2006.07.002

Tassa, C, Duffner J, Lewis T, Weissleder R, Schreiber S, Koehler A, and Shaw S. 2010. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem, 21: 14-19. DOI: https://doi.org/10.1021/bc900438a

Thring TS, Hili P, Naughton DP. 2009. Anti- collagenase,antielastase and anti-oxidant activities of extracts from 21 plants. BMC Compl Alter Med, 9: 1–11. doi:10.1186/1472-6882-9-27. DOI: https://doi.org/10.1186/1472-6882-9-27

Uttara B, Singh AV, Zamboni P, and Mahajan R. 2009. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options, Current Neuropharmacology, 7: 65-74. DOI: https://doi.org/10.2174/157015909787602823

http://www.tcd.uni-koeln.de/plants_download/download/ manual1.1.pdf accessed on 5th July 2017

http://www.rcsb.org/pdb/explore/explore.do?structureId accessed on 5th July 2017

http://yasara.org/ accessed on 5th July 2017

http://tox.charite.de/protox/ accessed on 2nd June 2017

http://www.rcsb.org/pdb/explore/explore.do?structureId accessed on 5th July 2017

http://tox.charite.de/protox/ accessed on 2nd June 2017

Conflict of interest: Non declare